Federal Multidistrict Litigation Court Sets Preliminary Discovery Plan for Consolidated Testosterone Drug Cases, Rottenstein Law Group LLP Reports

LongIsland.com

A discovery plan in the consolidated federal testosterone products matters will start the included cases along the path to trials or settlements.

Print Email

Rockville Centre, NY - August 27th, 2014 - United States District Judge Matthew F. Kennelly on August 26 filed a Preliminary Discovery Plan, as Case Management Order no. 7, in In re: Testosterone Replacement Therapy Products Liability Litigation (Case no. 14 C 1748/MDL No. 2545; U.S. District Court for the Northern District of Illinois), the federal multidistrict litigation matter that includes lawsuits filed against several manufacturers of prescription testosterone supplement medications. The Plan, according to the order, “is intended to conserve judicial and party resources, eliminate duplicative discovery, serve the convenience of the parties and witnesses, and promote the just and efficient conduct of this litigation.”  

“The entry of an order including a preliminary discover plan is an important step in the right direction,” said Rochelle Rottenstein, principal of the Rottenstein Law Group. “When the manufacturers of dangerous products are compelled to share information and documents with possible victims, the strengths and weaknesses of claims and defenses are often revealed, which can prompt settlement discussions.

According to allegations present in complaints filed in the MDL, millions of prescriptions have been written by doctors for testosterone products and supplement brands, to treat what has become known as “Low T.” Low T is characterized in marketing campaigns as a disorder that strikes middle-aged men, with symptoms that include fatigue, depression and a diminished sex drive. Some men, otherwise in good health, have allegedly suffered heart attacks and strokes after using the products. Only after falling ill did they discover that testosterone products can reportedly significantly increase the risk of heart attacks and strokes, a risk about which they were allegedly not warned by their doctors or the manufacturers. The alleged failure on the part of doctors and drug companies to warn about the risks of testosterone replacement therapy products has lead to the filing of lawsuits.

Anyone needing more information about the dangers of testosterone products should visit www.testosteroneinjuryfirm.com. Representatives of the Rottenstein Law Group are available to answer any questions, and there is a confidential, no-cost claim evaluation form that can be filled out in order to determine if one has grounds to file a testosterone products lawsuit.

About The Rottenstein Law Group LLP
The Rottenstein Law Group LLP is a New York-based firm that represents clients nationwide in mass tort actions. The firm was founded by Rochelle Rottenstein, who has more than two decades of experience as a lawyer, to represent clients hurt by defective medical devices and medications. (Attorney advertising. Prior results do not guarantee a similar outcome.)

For More Information, Please Contact:
The Rottenstein Law Group LLP
Rochelle Rottenstein, Esq.
100 Merrick Road, Suite 226W
Rockville Centre, NY 11570
(212) 933-9500 (office phone)
(212) 933-9980 (facsimile)
rochelle@rotlaw.com
plus.google.com/106070664376281033016